{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'present, measurements of instep and calf will be taken. Height will be measured at Screening', 'only.', 'Weight will be measured at Screening and every 12 weeks throughout the study (Weeks 12 and', '24 [or PW] during the Treatment Period and Weeks 36, 48, 60, and 72 [or PW] of the Follow-Up', 'Period). The dose on Day 1 of the double-masked Treatment Period will be based on the', 'Screening weight. The weight obtained at Week 12 can be used in dose calculations beginning at', 'Week 12 or Week 15.', '9.5.5.6 ECGs', '12-lead ECGs will be performed at Screening, Baseline, Weeks 3, 6, 12, and 24 (or PW) of the', 'Treatment Period, and Week 72 (or PW) of the Follow-Up Period. At infusion visits, the ECG', 'will be performed prior to the infusion. The results will be recorded as normal or abnormal on', 'the eCRF and all abnormal results will be evaluated as clinically (CS) or not clinically significant', '(NCS) by the Investigator. A copy of the ECG tracing will remain with the source documents.', '9.5.5.7 Clinical Laboratory Safety Tests', 'With the exception of urine pregnancy tests, a central study laboratory will be used for all', 'protocol-specified clinical laboratory parameters. Urine pregnancy tests will be performed', 'locally (see Section 9.5.5.2 for details). Details concerning the collection of these samples are', 'presented in Table 9.4.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 89 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Table 9.4', 'Schedule of Clinical Laboratory Safety Tests, Including Thyroid Panel and', 'Hyperglycemia Monitoring', 'Treatment Period', 'Follow-Up Period', 'Analysis Panel', 'BL', 'W1', 'W3', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W24', 'W28', 'W36', 'W48', 'W60', 'W72', 'SCR', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'Chemistry (excl.', 'X\u00b9', 'X', 'X', 'glucose)', 'Thyroid (FT3, FT4,', 'X', 'X', 'TSH) 2', 'Hematology', 'X', 'X', 'Glucose 3', 'X', 'HbA1c4', 'X', 'Urinalysis', 'X', 'Serum pregnancy 5', 'Urine pregnancy 5', 'X', 'X', 'X', 'X6', 'BL=Baseline; FT3=free triiodothyronine; FT4=free thyroxine; HbAlc=glycated hemoglobin; M=Month; SCR=Screening;', 'TSH=thyroid stimulating hormone; W=Week.', '1.', 'ALT/AST must be < 3 X the ULN and serum creatinine must be < 1.5 x the ULN according to age for randomization.', '2.', 'Subjects must be euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism (defined as FT4', 'and FT3 levels < 50% above or below the normal limits). Every effort should be made to correct the mild hypo- or', 'hyperthyroidism promptly and to maintain the euthyroid state for the full duration of the clinical trial.', '3.', 'Non-diabetic subjects will fast at Weeks 1 and 4 only. Diabetic subjects will fast for each blood glucose evaluation. NOTE:', 'Subjects with severe hyperglycemia that does not abate to mild or moderate intensity with anti-diabetic treatment (dose may', 'be skipped up to 2 times prior to permanently discontinuing study drug, see Section 9.4.6.3.2 for details) will be', 'permanently discontinued from study drug.', '4.', 'HbA1c must be < 9.0% for randomization. If the HbA1c is elevated and considered clinically significant at any time point', 'after Screening, it will be repeated approximately every 45 days until it returns to normal or baseline value.', '5.', 'Perform for female subjects of childbearing potential (including those with an onset of menopause <2 years prior to', 'Screening, non-therapy-induced amenorrhea for <12 months prior to Screening, or not surgically sterile [absence of ovaries', 'and/or uterus]).', '6.', 'Perform for female subjects of childbearing potential who enter the Follow-Up Period but discontinue study participation', 'prior to Week 48.', 'Instructions for the collection, handling and analysis of clinical laboratory samples will be', 'provided to the site prior to study site initiation.', '9.5.5.8 Immunogenicity Testing', 'Blood samples will be collected in a 5 mL SST collection tube for immunogenicity testing (ADA', 'and possibly Neutralizing Antibodies [NAb]) from all subjects prior to dosing on Day 1, prior to', 'dosing on Weeks 3 and 9, and at Week 24 (or PW) of the Treatment Period, and Weeks 36 and', '72 (or PW) of the Follow-Up Period. Samples will be collected, processed, and stored at > - -70\u00b0C', 'at the site until shipment to the central laboratory', 'will store the samples at > -70\u00b0C until shipment to', 'for immunogenicity testing (see', 'Table 6.1). If a subject tests positive for ADA after confirmatory and reactive titer testing, the', 'sample will then be tested for NAb. If the subject tests positive for NAb, he/she will be followed', \"until levels either revert to Baseline or the subject's value decreases or remains stable. Any\", 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 90 of 117']\n\n###\n\n", "completion": "END"}